These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 1659819

  • 1. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
    Treskes M, Holwerda U, Klein I, Pinedo HM, van der Vijgh WJ.
    Biochem Pharmacol; 1991 Nov 06; 42(11):2125-30. PubMed ID: 1659819
    [Abstract] [Full Text] [Related]

  • 2. The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.
    Treskes M, Holwerda U, Nijtmans LG, Pinedo HM, van der Vijgh WJ.
    Cancer Chemother Pharmacol; 1992 Nov 06; 29(6):467-70. PubMed ID: 1314713
    [Abstract] [Full Text] [Related]

  • 3. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate.
    Treskes M, Nijtmans LG, Fichtinger-Schepman AM, van der Vijgh WJ.
    Biochem Pharmacol; 1992 Mar 03; 43(5):1013-9. PubMed ID: 1313234
    [Abstract] [Full Text] [Related]

  • 4. Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.
    Treskes M, Nijtmans L, Fichtinger-Schepman AM, van der Vijgh WJ.
    Anticancer Res; 1992 Mar 03; 12(6B):2261-5. PubMed ID: 1338281
    [Abstract] [Full Text] [Related]

  • 5. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles.
    Dedon PC, Borch RF.
    Biochem Pharmacol; 1987 Jun 15; 36(12):1955-64. PubMed ID: 2954556
    [Abstract] [Full Text] [Related]

  • 6. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
    Endo K, Akamatsu K, Matsumoto T, Morikawa K, Koizumi M, Mitsui H, Koizumi K.
    Anticancer Res; 1992 Jun 15; 12(1):49-58. PubMed ID: 1567181
    [Abstract] [Full Text] [Related]

  • 7. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
    Chang MJ, Yu WD, Reyno LM, Modzelewski RA, Egorin MJ, Erkmen K, Vlock DR, Furmanski P, Johnson CS.
    Cancer Res; 1994 Oct 15; 54(20):5380-6. PubMed ID: 7923169
    [Abstract] [Full Text] [Related]

  • 8. Similar effects of cis-diamminedichloroplatinum(II) and cis-diammine-1,1-cyclobutanedicarboxylatoplatinum(II) on sodium-coupled glucose uptake in renal brush-border membrane vesicles.
    Potdevin S, Courjault-Gautier F, Ripoche P, Toutain HJ.
    Arch Toxicol; 1998 Oct 15; 72(10):663-70. PubMed ID: 9851683
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity and cellular accumulation of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum( II) monohydrate, in cisplatin-sensitive and -resistant murine P388 leukemia cells.
    Kamisango K, Matsumoto T, Akamatsu K, Morikawa K, Tashiro T, Koizumi K.
    Jpn J Cancer Res; 1992 Mar 15; 83(3):304-11. PubMed ID: 1582895
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
    Knox RJ, Friedlos F, Lydall DA, Roberts JJ.
    Cancer Res; 1986 Apr 15; 46(4 Pt 2):1972-9. PubMed ID: 3512077
    [Abstract] [Full Text] [Related]

  • 11. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
    Treskes M, van der Vijgh WJ.
    Cancer Chemother Pharmacol; 1993 Apr 15; 33(2):93-106. PubMed ID: 8261581
    [Abstract] [Full Text] [Related]

  • 12. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Alvarez-Valdés A, Pérez JM, López-Solera I, Lannegrand R, Continente JM, Amo-Ochoa P, Camazón MJ, Solans X, Font-Bardía M, Navarro-Ranninger C.
    J Med Chem; 2002 Apr 25; 45(9):1835-44. PubMed ID: 11960495
    [Abstract] [Full Text] [Related]

  • 13. Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action.
    Los G, Verdegaal E, Noteborn HP, Ruevekamp M, de Graeff A, Meesters EW, ten Bokkel Huinink D, McVie JG.
    Biochem Pharmacol; 1991 Jul 05; 42(2):357-63. PubMed ID: 1859450
    [Abstract] [Full Text] [Related]

  • 14. In vitro antitumor activity of a new platinum complex, DWA2114R against human tumor cell lines.
    Akamatsu K, Saito H, Tsunenari T, Matsumoto T, Morikawa K, Koizumi M, Mitsui H, Koizumi K.
    Anticancer Res; 1993 Jul 05; 13(6A):2261-5. PubMed ID: 8297143
    [Abstract] [Full Text] [Related]

  • 15. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.
    Los G, van Vugt MJ, den Engelse L, Pinedo HM.
    Biochem Pharmacol; 1993 Oct 05; 46(7):1229-37. PubMed ID: 8216374
    [Abstract] [Full Text] [Related]

  • 16. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
    Kim DK, Kim HT, Cho YB, Tai JH, Ahn JS, Kim TS, Kim KH, Hong WS.
    Cancer Chemother Pharmacol; 1995 Oct 05; 35(5):441-5. PubMed ID: 7850928
    [Abstract] [Full Text] [Related]

  • 17. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
    Robson H, Meyer S, Shalet SM, Anderson E, Roberts S, Eden OB.
    Med Pediatr Oncol; 2002 Dec 05; 39(6):573-80. PubMed ID: 12376980
    [Abstract] [Full Text] [Related]

  • 18. Experimental studies of cis-diamminedichloroplatinum (II) and cis-diammine-1, 1-cyclobutandicarboxylate platinum (II) combination therapy for malignant gynecologic tumors.
    Kato N.
    Asia Oceania J Obstet Gynaecol; 1993 Dec 05; 19(4):467-76. PubMed ID: 8135680
    [Abstract] [Full Text] [Related]

  • 19. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
    Treskes M, Boven E, Holwerda U, Pinedo HM, van der Vijgh WJ.
    Cancer Res; 1992 Apr 15; 52(8):2257-60. PubMed ID: 1313740
    [Abstract] [Full Text] [Related]

  • 20. [Probability of the combination use of cisplatin and carboplatin].
    Kobayashi K, Hino M, Hayashihara K, Niitani H.
    Nihon Gan Chiryo Gakkai Shi; 1990 Nov 20; 25(11):2684-92. PubMed ID: 2277219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.